Esperion Therapeutics, Inc.
ESPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $87 | $82 | $65 | $69 |
| % Growth | 6% | 26.8% | -6% | – |
| Cost of Goods Sold | $55 | $29 | $32 | $26 |
| Gross Profit | $32 | $54 | $33 | $43 |
| % Margin | 36.5% | 65.4% | 51.5% | 62.9% |
| R&D Expenses | $14 | $7 | $13 | $11 |
| G&A Expenses | $0 | $0 | $0 | $11 |
| SG&A Expenses | $42 | $40 | $43 | $37 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $26 |
| Other Operating Expenses | -$14 | $0 | $0 | $0 |
| Operating Expenses | $42 | $47 | $56 | $48 |
| Operating Income | -$10 | $7 | -$22 | -$4 |
| % Margin | -11.4% | 8.6% | -34% | -6.4% |
| Other Income/Exp. Net | -$21 | -$20 | -$18 | -$17 |
| Pre-Tax Income | -$31 | -$13 | -$40 | -$21 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$31 | -$13 | -$40 | -$21 |
| % Margin | -35.9% | -15.4% | -62.2% | -30.8% |
| EPS | -0.16 | -0.024 | -0.21 | -0.11 |
| % Growth | -561.2% | 88.5% | -90.9% | – |
| EPS Diluted | -0.2 | -0.024 | -0.21 | -0.11 |
| Weighted Avg Shares Out | 198 | 197 | 196 | 196 |
| Weighted Avg Shares Out Dil | 198 | 197 | 196 | 196 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $22 | $20 | $19 | $16 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$9 | $8 | -$21 | -$5 |
| % Margin | -10.6% | 9.5% | -32.3% | -7% |